Intellectual Property India Publishes Patent Application for 'Pluripotent Stem Cell-Derived T Cell Populations And Progenitors Thereof' Filed by Garuda Therapeutics, Inc.

MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517042277 A) filed by Garuda Therapeutics, Inc., Cambridge, U.S.A., on May 1, for 'pluripotent stem cell-derived t cell populations and progenitors thereof.'

Inventor(s) include Shah, Dhvanit.

The application for the patent was published on Aug. 8, under issue no. 32/2025.

According to the abstract released by the Intellectual Property India: "In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for efficient ex vivo processes for developing progenitor T cells and T cell populations (including but not limited to CD4+CD8+ "double positive" T cells, as well as single positive CD4+ T helper cells and CD8+ cytotoxic T cells, and T regulatory cells) from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or lymphoid organs. The present invention in some aspects provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy."

The patent application was internationally filed on Oct. 05, 2023, under International application No.PCT/US2023/076110.

Disclaimer: Curated by HT Syndication.